Table 2.
COVID-19 and amyloidosis
| Patient | Age/Gender AL type | Current treatment | Amyloid status at COVID- 19 infection | Time from diagnosis (Months) | Prior lines of thera py | Immunopa resis and ALC* at COVID-19 | Summary Status (alive/dead) Infection severity (Inf) Treatment (Trx) Vaccine status (Vax) |
|---|---|---|---|---|---|---|---|
| 1 | 65/MAL amyloidosis, Stage IIIA | CyBorD | PR | 6 | 0 | Yes (IgG and IgM low) ALC = 1.3 | Status: Alive |
| Inf: Mild | |||||||
| Trx: Sotrovimab | |||||||
| Vax:Postvaccinex3 | |||||||
| 2 | 46/FAL amyloidosis, Stage II | CyBorD | NR | 5 | 0 | Yes (IgG and IgA low) ALC = 2.6 | Status: Alive |
| Inf: Moderate | |||||||
| Trx: No treatment | |||||||
| Vax: Unvaccinated | |||||||
| 3 | 86/MAL amyloidosis, Stage II | Lenalidomide and dexamethasone | VGPR | 96 | 1 | Yes (IgG and IgM low) ALC = 0.9 | Status: Alive |
| Inf: Mild-Moderate | |||||||
| Trx: Sotrovimab | |||||||
| Vax: Postvaccinex3 | |||||||
| 4 | 64/FAL amyloidosis, Stage II | Daratumumab | VGPR | 36 | 1 | Yes (IgG and IgM low) ALC = 2.3 | Status: Alive |
| Inf: Mild | |||||||
| Trx: No treatment | |||||||
| Vax: Unvaccinated | |||||||
| 5 | 61/FAL amyloidosis, Stage II | None | VGPR | 36 | 1 | No ALC = 1.6 | Status: Alive |
| Inf: Mild | |||||||
| Trx: No treatment | |||||||
| Vax: Post vaccinex3 | |||||||
| 6 | 56/MAL amyloidosis, Stage II | Lenalidomide and dexamethasone | VGPR | 40 | 1 | No ALC = 1.6 | Status: Alive |
| Inf: Mild | |||||||
| Trx: No treatment | |||||||
| Vax: Unvaccinated | |||||||
| 7 | 76/MAL amyloidosis, Stage II and co-diagnosis of CLL | CyBorMe | VGPR | 12 | 0 | No ALC = 11 | Status: Alive |
| Inf: Severe. Pneumonia required hospital admission | |||||||
| Trx: Dexamethasoneand Remdesivir | |||||||
| Vax: Postvaccinex2 | |||||||
| 8 | 52/MAL amyloidosis, Stage II | CyBorD | NA | 1 | 0 | Yes (IgG low) ALC = 1.9 | Status: Alive |
| Inf: Moderate. Pneumonia. No hospitalization | |||||||
| Trx: Dexamethasone | |||||||
| Vax: Unvaccinated | |||||||
| 9 | 67/MAL amyloidosis, Stage IIIA | None | Untreated | < 1 | 0 | Yes (IgA and IgM low) ALC = 2.3 | Status: Alive |
| Inf: Moderate. Pneumonia required hospital admission | |||||||
| Trx: Sotrovimab | |||||||
| Vax: Postvaccinex2 | |||||||
| 10 | 62/FAL amyloidosis, Stage IIIB | None | Untreated | < 1 | 0 | Yes (IgA and IgM low) ALC = 1.3 | Status: Died 3 months post Covid-19 infection |
| Inf: Mild | |||||||
| Trx: Untreated | |||||||
| Vax: Postvaccinex2 | |||||||
| 11 | 79/F Localized AL amyloid (Lung) | None | Untreated | 0 | 0 | No ALC = 2.0 | Status: Alive |
| Inf: Mild-Moderate | |||||||
| Trx: Dexamethasone | |||||||
| Vax: Postvaccinex3 | |||||||
| 12 | 80/MATTR with cardiac and nerve involvement | Tafamidis | NA | 36 | 0 | Unknown ALC = 1 | Status: Alive |
| Inf: Moderate. Pneumonia required hospital admission | |||||||
| Trx: Dexamethasone and Remdesivir | |||||||
| Vax: Unvaccinated | |||||||
| 13 | 76/MATTR with cardiac involvement | Supportive Care | NA | 12 | 0 | Unknown ALC = 0.3 | Status: Died |
| Inf: Severe. Pneumonia required hospital admission | |||||||
| Trx: Dexamethasose and Remdesivir | |||||||
| Vax: Unvaccinated | |||||||
| 14 | 87/MATTR with cardiac involvement | Tafamidis | NA | 24 | 0 | No ALC = 1.4 | Status: Alive |
| Inf: Mild | |||||||
| Trx: No treatment | |||||||
| Vax: Postvaccinex3 | |||||||
| 15 | 89/MATTR with cardiac involvement | Supportive Care | NA | 12 | 0 | Unknown ALC = 2.3 | Status: Died 6 months after Covid-19 infection |
| Inf: Moderate. Pneumonia. No hospitalization | |||||||
| Trx: Prednisone | |||||||
| Vax: Postvaccinex1 |
*Absolute lymphocyte count (ALC) measured in 10E9/L